Astellas Pharma Inc. - Product Pipeline Review - 2016

Published: May, 2016 | Pages: 285 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Astellas Pharma Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Astellas Pharma Inc. - Product Pipeline Review - 2016', provides an overview of the Astellas Pharma Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Astellas Pharma Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Astellas Pharma Inc.
- The report provides overview of Astellas Pharma Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Astellas Pharma Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Astellas Pharma Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Astellas Pharma Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Astellas Pharma Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Astellas Pharma Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Astellas Pharma Inc. Snapshot 7
Astellas Pharma Inc. Overview 7
Key Information 7
Key Facts 7
Astellas Pharma Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Astellas Pharma Inc. - Pipeline Review 16
Pipeline Products by Stage of Development 16
Pipeline Products - Monotherapy 17
Pipeline Products - Combination Treatment Modalities 18
Pipeline Products - Partnered Products 19
Pipeline Products - Out-Licensed Products 22
Astellas Pharma Inc. - Pipeline Products Glance 24
Astellas Pharma Inc. - Late Stage Pipeline Products 24
Astellas Pharma Inc. - Clinical Stage Pipeline Products 27
Astellas Pharma Inc. - Early Stage Pipeline Products 29
Astellas Pharma Inc. - Drug Profiles 33
linaclotide 33
solifenacin succinate 36
tacrolimus ER 38
(ipragliflozin + sitagliptin phosphate) 39
(mirabegron + solifenacin succinate) 40
amenamevir 42
ASP-0113 43
bendamustine hydrochloride 44
degarelix acetate 47
enzalutamide 49
evolocumab 53
fidaxomicin 56
gilteritinib fumarate 59
mirabegron ER 61
naquotinib mesylate 63
peficitinib hydrobromide 64
quetiapine fumarate ER 66
romosozumab 67
roxadustat 69
AGS-16C3F 72
ASP-1707 73
ASP-3662 74
ASP-7962 75
ASP-8232 76
erlotinib hydrochloride 77
FG-2216 80
ipragliflozin 82
linsitinib 86
MA09-hRPE 89
regadenoson 91
blinatumomab 93
AGS-67E 97
ASG-15ME 99
ASP-0819 100
ASP-2205 101
ASP-2905 102
ASP-4132 103
ASP-4345 104
ASP-5094 105
ASP-5878 106
ASP-6282 107
ASP-6294 108
ASP-7266 109
ASP-7398 110
ASP-8062 111
enfortumab vedotin 112
OSI-930 113
AS-1069562 114
AS-1669058 115
AS-1940477 116
AS-2034178 117
AS-2077715 118
AS-2444697 119
AS-2521780 120
AS-2575959 121
AS-2715348 122
AS-2795440 123
AS-288640100 124
ASP-1017 125
ASP-1645 126
ASP-3258 127
ASP-5736 128
ASP-6537 129
ASP-7663 130
ASP-9133 131
ASP-9726 132
FK-886 133
Gene Therapy to Activate mVChR1 for Retinits Pigmentosa 135
KB-425796C 136
Monoclonal Antibody Conjugates for Oncology 137
OSI-296 138
Small Molecule 2 for Epilepsy 140
Small Molecule 3 for Epilepsy 141
Small Molecule 4 for Epilepsy 142
Small Molecule for Epilepsy 143
Small Molecule to Block N-type Calcium and hERG Potassium Channels for Neuropathic Pain 144
Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer 145
Small Molecule to Inhibit JAK3 for Heart Transplantation 146
Small Molecule to Inhibit PDE10A for Schizophrenia 147
Small Molecule to Inhibit TAK1 for Ovarian Cancer 148
Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes 149
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine 150
Small Molecules to Inhibit DAAO for Cognitive Disorders 151
Small Molecules to Inhibit RANKL for Osteoclastogenesis 152
Stem Cell Therapy for Autoimmune Diseases 153
Stem Cell Therapy for Corneal Blindness 154
Stem Cell Therapy for Glaucoma 155
Stem Cell Therapy for Ophthalmic Disorders 156
UMN-0901 157
AS-1468240 158
Drugs for Pancreatic Cancer 159
KB-425796A 160
Monoclonal Antibodies for Oncology 161
Small Molecules for Non-Neuromuscular and Neuromuscular Disorders 162
Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders 163
Small Molecules to Inhibit ACK1 for Oncology 164
Astellas Pharma Inc. - Pipeline Analysis 165
Astellas Pharma Inc. - Pipeline Products by Target 165
Astellas Pharma Inc. - Pipeline Products by Route of Administration 175
Astellas Pharma Inc. - Pipeline Products by Molecule Type 176
Astellas Pharma Inc. - Pipeline Products by Mechanism of Action 177
Astellas Pharma Inc. - Recent Pipeline Updates 184
Astellas Pharma Inc. - Dormant Projects 256
Astellas Pharma Inc. - Discontinued Pipeline Products 258
Discontinued Pipeline Product Profiles 260
Astellas Pharma Inc. - Company Statement 268
Astellas Pharma Inc. - Locations And Subsidiaries 269
Head Office 269
Other Locations & Subsidiaries 269
Astellas Pharma Inc. - Key Manufacturing Facilities 275
Appendix 276
Methodology 276
Coverage 276
Secondary Research 276
Primary Research 276
Expert Panel Validation 276
Contact Us 276
Disclaimer 277

List of Tables

Astellas Pharma Inc., Key Information 15
Astellas Pharma Inc., Key Facts 15
Astellas Pharma Inc. - Pipeline by Indication, 2016 17
Astellas Pharma Inc. - Pipeline by Stage of Development, 2016 24
Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2016 25
Astellas Pharma Inc. - Combination Treatment Modalities in Pipeline, 2016 26
Astellas Pharma Inc. - Partnered Products in Pipeline, 2016 27
Astellas Pharma Inc. - Partnered Products/ Combination Treatment Modalities, 2016 28
Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2016 30
Astellas Pharma Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 31
Astellas Pharma Inc. - Pre-Registration, 2016 32
Astellas Pharma Inc. - Filing rejected/Withdrawn, 2016 33
Astellas Pharma Inc. - Phase III, 2016 34
Astellas Pharma Inc. - Phase II, 2016 35
Astellas Pharma Inc. - Phase I, 2016 36
Astellas Pharma Inc. - IND/CTA Filed, 2016 37
Astellas Pharma Inc. - Preclinical, 2016 38
Astellas Pharma Inc. - Discovery, 2016 40
Astellas Pharma Inc. - Pipeline by Target, 2016 173
Astellas Pharma Inc. - Pipeline by Route of Administration, 2016 183
Astellas Pharma Inc. - Pipeline by Molecule Type, 2016 184
Astellas Pharma Inc. - Pipeline Products by Mechanism of Action, 2016 185
Astellas Pharma Inc. - Recent Pipeline Updates, 2016 192
Astellas Pharma Inc. - Dormant Developmental Projects,2016 264
Astellas Pharma Inc. - Discontinued Pipeline Products, 2016 266
Astellas Pharma Inc., Other Locations 277
Astellas Pharma Inc., Subsidiaries 278
Astellas Pharma Inc., Key Manufacturing Facilities 283